# Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

> **NCT04203056** · PHASE4 · TERMINATED · sponsor: **University of California, Los Angeles** · enrollment: 15 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder, Depressive Type
- Schizophreniform Disorder

## Interventions

- **DRUG:** Aripiprazole Lauroxil
- **DRUG:** ARI-ORAL
- **DRUG:** AL-NCD

## Key facts

- **NCT ID:** NCT04203056
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-16
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Withdraw of financial support by industry collaborator
- **Last updated:** 2023-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203056, "Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04203056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*